FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

Moore, KN; Vergote, I; Oaknin, A; Colombo, N; Banerjee, S; Oza, AM; Pautier, P; Kelly, CM; Malek, K; Birrer, MJ

Annals Of Oncology

FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

Author:

Moore, KN

Vergote, I ; Oaknin, A ; Colombo, N ; Banerjee, S ; Oza, AM ; Pautier, P ; Kelly, CM ; Malek, K ; Birrer, MJ

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Annals Of Oncology FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

Author:

Keywords:

About us

Our services

Our solutions